Atezolizumab in patients with advanced non-small cell lung cancer and history of asymptomatic, treated brain metastases: exploratory analyses of the phase III OAK study

Brain metastases are a frequent complication of advanced non-small cell lung cancer (NSCLC); they occur in 20% to 40% of patients (often within the first 2 years of primary diagnosis), are associated with poor survival, and have very few systemic treatment options [1 –4].

Source: Lung Cancer - December 19, 2018 Category: Cancer & Oncology Authors: Shirish M. Gadgeel, Rimas V. Lukas, Jerome Goldschmidt, Paul Conkling, Keunchil Park, Diego Cortinovis, Filippo de Marinis, Achim Rittmeyer, Jyoti D. Patel, Joachim von Pawel, Carol O ’Hear, Catherine Lai, Sylvia Hu, Marcus Ballinger, Alan Sandler, Maya Source Type: research